Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Dr Hillman on Identifying New Therapy Candidates in Adult-Type Granulosa Cell Tumor

January 31st 2025

R. Tyler Hillman, MD, PhD, discusses ways of identifying new drug therapy candidates in patients with adult-type granulosa cell tumor of the ovary.

Dr Secord on the National Academies of Sciences, Engineering, and Medicine’s Assessment of Women’s Health Research at the NIH

January 31st 2025

Angeles Alvarez Secord, MD, MHSc, discusses findings from the consensus report published by the National Academies of Sciences, Engineering, and Medicine committee.

Molecular Subtyping Predicts Recurrence and Survival Benefits in Endometrial Cancer

January 30th 2025

The addition of chemotherapy to radiation therapy following surgery conferred a benefit in certain endometrial cancer molecular subtypes.

Observational Data Challenge p53 Expression as a Surrogate Marker for TP53 Mutations in High-Risk Endometrial Cancer

January 30th 2025

An observational cohort study determined that discordance exists between p53 protein expression and TP53 mutation status in high-risk endometrial cancer.

Dr Hinchcliff on the Addition of Dostarlimab to Chemotherapy in Advanced/Recurrent Endometrial Cancer

January 27th 2025

Emily Hinchcliff, MD, MPH, discusses the addition of dostarlimab to standard-of-care chemotherapy in patients with advanced/recurrent endometrial cancer.

European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer

January 20th 2025

Frontline dostarlimab plus chemotherapy has been approved in the EU for all adult patients with primary advanced or recurrent endometrial cancer.

The OncFive: Top Oncology Articles for the Week of 1/5

January 11th 2025

Sunvozertinib gets priority review in EGFR-mutated NSCLC, iparomlimab/tuvonralimab combination elicits responses in cervical cancer, and more.

Dr Goldsberry on PARP Inhibitor Selection in Advanced Ovarian Cancer

January 9th 2025

Whitney Goldsberry, MD, discusses considerations for selecting a PARP inhibitor in the maintenance treatment of ovarian cancer.

Multidisciplinary Collaboration Is Crucial in Managing Ocular Toxicities of Mirvetuximab Soravtansine in Gynecologic Tumors

January 8th 2025

Rebecca Arend, MD, and Kathryn Lyle, CRNP, discuss their approach to managing ocular and other treatment-related toxicities associated with mirvetuximab soravtansine.

Iparomlimab/Tuvonralimab Plus Chemo ± Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer

January 6th 2025

First-line paromlimab/tuvonralimab plus chemotherapy with or without bevacizumab was active in recurrent/metastatic cervical cancer.

Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies

December 31st 2024

Experts detail how recent NCCN guideline changes in dozens of tumor types are affecting their practices, and we gather all the NCCN updates in a slideshow.

Shaking Up Gynecologic Cancer Treatment With Mentorship and Patient-Centric Care

December 28th 2024

Carol Aghajanian, MD, has stayed at the forefront of innovation in gynecologic oncology—and she credits her patients and their conversations in retaining that role.

Neratinib Joins NCCN Guidelines for HER2-Mutated Cervical Cancer

December 23rd 2024

The NCCN Guidelines have been updated to include neratinib for HER2-mutated recurrent/metastatic cervical cancer in the second line or later.

Lunresertib Plus Camonsertib Produces Durable Responses in Advanced Endometrial, Ovarian Cancer

December 19th 2024

Lunresertib plus camonsertib demonstrated efficacy and safety in heavily pretreated endometrial cancer and platinum-resistant ovarian cancer.

Dostarlimab Plus Chemo Earns Positive CHMP Opinion for Expanded Indication in Advanced Endometrial Cancer

December 16th 2024

The EMA’s CHMP has recommended the approval of an expanded indication for dostarlimab plus chemotherapy in primary advanced/recurrent endometrial cancer.

New ADCs Join NCCN Guidelines for Gynecologic Cancers Representing Step Forward

December 10th 2024

Stephanie Gaillard, MD, PhD, details cervical and ovarian cancer NCCN guideline updates, as well as unmet needs associated with molecular markers.

Immunotherapy Redefines Standard of Care for Frontline Advanced Endometrial Cancer

December 5th 2024

Monica H. Vetter, MD, discusses the integration of immunotherapy into chemotherapy regimens for frontline advanced endometrial cancer.

FDA Grants Fast Track Designation to CRB-701 in Relapsed/Refractory Cervical Cancer

December 5th 2024

CRB-701 has received FDA fast track designation for the treatment of adult patients with relapsed/refractory metastatic cervical cancer.

Cadonilimab Plus Chemotherapy Provides Frontline Survival Benefit in Metastatic Cervical Cancer

December 3rd 2024

Cadonilimab/chemotherapy ± bevacizumab improved survival outcomes vs placebo in frontline persistent, recurrent, or metastatic cervical cancer.

NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer

December 3rd 2024

Fruquintinib plus sintilimab injection has received conditional approval from the NMPA for mismatch repair–proficient advanced endometrial cancer.